Incyte Corp
(BSP:I1NC34)
R$
221.1
0 (0%)
Market Cap: 85.19 Bil
Enterprise Value: 74.99 Bil
PE Ratio: 552.00
PB Ratio: 4.70
GF Score: 77/100 Incyte Corp at Evercore ISI HealthCONx Conference Transcript
Nov 30, 2023 / 05:30PM GMT
Release Date Price:
R$160.02
Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst
All right. Welcome, everyone. This is Gavin Clark-Gartner with the Evercore ISI Biotech research team, and I'm really happy to be here with the Incyte team. We have Herve Hoppenot, who is the CEO; and we have Christiana Stamoulis, the Chief Financial Officer. Thanks for joining.
Christiana Stamoulis
Incyte Corporation - Executive VP & CFO
Thank you.
Herve Hoppenot
Incyte Corporation - CEO & Chairman
Thank you for inviting us in Miami.
Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst
Absolutely. All right. Maybe I'll just kind of turn it over for any opening remarks, if there's anything you want to frame or hit on first?
Herve Hoppenot
Incyte Corporation - CEO & Chairman
I mean, I can try to quickly describe a little bit where we are in the evolution of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot